Cited by 39Endometriosis Research and TreatmentReproductive Health and ContraceptionEctopic Pregnancy Diagnosis and Management

Postoperative levonorgestrel‐releasing intrauterine system versus oral contraceptives after gonadotropin‐releasing hormone agonist treatment for preventing endometrioma recurrence

Open access
Cho, Sihyun, Jung, Ji Ann, Lee, Yousun, Kim, Hye Yeon, Seo, Seok Kyo, Choi, Young Sik, Lee, Ji Sung, Lee, Byung Seok·2014·Acta Obstetricia et Gynecologica Scandinavica

Abstract

Objective: Although the levonorgestrel‐releasing intrauterine system (LNG‐IUS) is effective in reducing the recurrence of endometriosis‐associated pain, its efficacy in preventing endometrioma recurrence is questionable. We compared the efficacy of postoperative use of LNG‐IUS with oral contraceptives (OC) for preventing endometrioma recurrence. Design: A retrospective cohort study. Setting: Medical university hospital. Population: Ninety‐nine women with endometriomas. Methods: A chart review was performed of women of reproductive age who had undergone laparoscopic surgery for endometrioma followed by three cycles of gonadotropin‐releasing hormone agonist (leuprolide acetate) treatment. Women were categorized into two groups: a group that had postoperative LNG‐IUS placement (n = 42) and a group that received postoperative, cyclic, low‐dose, monophasic,OC s (n = 57). Main outcome measures: Endometrioma recurrence was analyzed according to several clinical variables and postoperative treatment modalities. Results: During the follow‐up period (median 17 months), recurrent endometriomas were detected in eight women (8.1%). Patients with LNG‐IUS had a recurrence rate of 4.8% (2/42), whereas women receiving OC had a recurrence rate of 10.5% (6/57). Cumulative recurrence‐free survival assessment revealed that mean disease‐free survival times for both groups were similar, but that for LNG‐IUS was slightly longer than that for OC, with statistical significance (34.4 ± 1.0 months, 95% confidence interval 32.3–36.5, vs. 33.4 ± 1.3 months, 95% confidence interval 30.8–36.0,p = 0.045). Univariate analysis revealed a hazard ratio of 0.178 (95% confidence interval 0.029–1.075) (p = 0.060) for postoperative LNG‐IUS use and endometrioma recurrence. However, for the multivariate regression analysis, only postoperative serum CA 125 levels were significantly associated with endometrioma recurrence (hazard ratio 1.012,p = 0.010). Conclusions: Postoperative LNG‐IUS use seemed to be comparable to the use of cyclic OC in preventing endometrioma recurrence.

Integrity signals

Registry

Crossref · 10.1111/aogs.12294

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two retrospective studies found that postoperative LNG-IUS use seems comparable to COC in preventing endometrioma recurrence.

    “Two retrospective studies [88,89] compared the efficacy of postoperative use LNG-IUS with COC for preventing endometrioma recurrence. In both cases, postoperative LNG-IUS use seems comparable to that of COC in preventing endometrioma recurrence.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cho, S., Jung, J. A., Lee, Y., Kim, H. Y., Seo, S. K., Choi, Y. S., Lee, J. S., & Lee, B. S.
Affiliations
  • Yonsei University (KR)
  • Gachon University (KR)
Corresponding author
Lee, Byung Seok
Venue
Acta Obstetricia et Gynecologica Scandinavica
Publisher
Wiley
Published
2013-12-17
Volume
93
Issue
1
Pages
38-44
ISSN
  • 0001-6349 (ISSN-L)
  • 1600-0412
OpenAlex
W2021451858
Cited by
39
References
37
Citations by year
2026: 3 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 3
FWCI
2.82
Type
journal article
Language
en
Open access
Locations
  • Acta Obstetricia Et Gynecologica Scandinavica (publishedVersion)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Funders
Yonsei University
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
Keywords
endometrioma recurrence, levonorgestrel-releasing intrauterine system, oral contraceptives, GnRH agonist, leuprolide, postoperative hormonal therapy, CA125, endometriosis-associated pain, disease-free survival, endometriosis surgery, recurrence prevention, levonorgestrel
MeSH terms
Adult, Contraceptives, Oral, Hormonal, Endometriosis, Female, Humans, Intrauterine Devices, Medicated, Gonadotropin-Releasing Hormone, Middle Aged, Retrospective Studies, Leuprolide, Levonorgestrel, Disease-Free Survival, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review